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Abstract 
Tubulin-binding vascular-disrupting agents (VDA) are cur- rently in clinical trials for 
cancer therapy but the factors that influence tumor susceptibility to these agents are 
poorly understood. We evaluated the consequences of modifying tumor vascular 
morphology and function on vascular and therapeutic response to combretastatin-A4 3-O 
-phosphate (CA-4-P), which was chosen as a model VDA. Mouse fibro- sarcoma cell 
lines that are capable of expressing all vascular endothelial growth factor (VEGF) 
isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or 
VEGF188) were developed under endogenous VEGF promoter control. Once tumors 
were established, VEGF isoform expression did not affect growth or blood flow rate. 
However, VEGF188 was uniquely associated with tumor vascular maturity, resistance to 
hemorrhage, and resistance to CA-4-P. Pericyte staining was much greater in VEGF188 
and control tumors than in VEGF120 and VEGF164 tumors. Vascular volume was 
highest in VEGF120 and control tumors (CD31 staining) but total vas- cular length was 
highest in VEGF188 tumors, reflecting very narrow vessels forming complex vascular 
networks. I.v. administered 40 kDa FITC-dextran leaked slowly from the vasculature of 
VEGF188 tumors compared with VEGF120 tumors. Intravital microscopy measurements 
of vascular length and RBC velocity showed that CA-4-P produced signi- ficantly more 
vascular damage in VEGF120 and VEGF164 tumors than in VEGF188 and control 
tumors. Importantly, this translated into a similar differential in therapeutic response, as 
determined by tumor growth delay. Results imply differences in signaling pathways 
between VEGF isoforms and suggest that VEGF isoforms might be useful in vascular- 
disrupting cancer therapy to predict tumor susceptibility to VDAs. 
Introduction 
Disodium combretastatin-A4 3-O -phosphate (CA-4-P) is the lead compound of a group 
of tubulin-binding agents that act as vascular-disrupting agents (VDA) in solid tumors (1, 
2). CA-4-P is active in human cancers (3) and is currently in phase II clinical trials in 
combination with conventional treatments (4).4 VDAs cause a catastrophic collapse of 
blood flow to solid tumors and thus form a conceptually distinct group from the 
antiangiogenic agents (5). 
Despite the progress of VDAs to clinical trials, and some evidence for improved patient 
survival upon adding VDA treatment to conventional chemotherapy (6), the reasons for 
the susceptibility of the tumor vasculature to VDAs remain unclear. Tumor blood vessels 
are generally considered to be immature. Thus, genetic modification of tumor cells to 
modulate expression of key molecules involved in vascular maturation provides a 
potential route for investigating the factors that influence the response of the tumor 
vasculature to VDAs. 
Vascular endothelial growth factor A (VEGF-A or simply VEGF) is a key stimulator of 
tumorigenic angiogenesis (7) and acts as a mitogen, chemoattractant, survival factor, 
vasodilator, and perme- ability factor (8). Human and mouse VEGF mRNA is transcribed 
from eight exons and alternatively spliced to give rise to a number of isoforms of the 
protein product (9), the most prevalent consisting of 121, 165, and 189 amino acids in the 
human and 120, 164, and 188 in the mouse (Fig. 1A). VEGF120/121 lacks the heparin-
binding site and is readily diffusible, whereas VEGF188/189 is tightly bound to 
proteoglycans in the extracellular matrix or on the cell surface and VEGF164/165 has 
intermediate properties. These isoforms are found in most normal tissues and have 
affinity for the VEGF receptors, FLT1 (VEGFR1) and KDR (VEGFR2; refs. 10, 11). 
VEGF121 and VEGF165 are the most prevalent forms in human cancers (12, 13). 
Using Cre/Lox technology, mice expressing only single isoforms of VEGF, known as 
Vegfa120/120, Vegfa164/164, and Vegfa188/188 mice, have been developed (14, 15). Their 
analysis revealed different roles for the individual VEGF isoforms in vascular growth and 
patterning during development. In particular, VEGF164 was suffi- cient for 
developmental angiogenesis and neonatal growth, and VEGF120 supported endothelial 
cell proliferation and vasculogenesis; however, angiogenic vessel branching was 
impaired and vessels were hemorrhagic (16). VEGF188 was essential for the formation 
of a normal cardiovasculature in 50% of mice (14, 15). 
In the current study, we used the single VEGF isoform-expressing mice and the 
counterpart wild-type mice to develop mouse fibrosarcoma cell lines from embryo 
fibroblasts. We reasoned that the different VEGF isoforms would give rise to tumors with 
very different vascular characteristics that could be used to investigate susceptibility to 
CA-4-P. The method of producing the tumor lines was substantially different from 
previous studies in which overexpression of individual VEGF isoforms was used (13, 
17), ensuring that VEGF gene transcription was under the control of the endogenous 
VEGF promoter and thus susceptible to environmental 
control. We gained new insights into the differential effects of VEGF isoforms in tumors 
by using intravital microscopy and tumor uptake of i.v. administered markers to measure 
functional vascular end points, in addition to measuring vascular morphology and tumor 
growth, with and without CA-4-P. 
Materials and Methods 
Animal experiments were conducted in accordance with the United Kingdom Animals (Scientific 
Procedures) Act 1986 and with local ethical approval. CA-4-P was kindly provided by Professor 
G.R. Pettit (Arizona State University, Tempe, AZ). 
Tumor cell lines. Primary mouse embryo fibroblasts expressing single isoforms of VEGF (120, 
164, or 188) only or all isoforms (Fig. 1A) were isolated from 13.5 dpc embryos produced by 
heterozygous breeding pairs of single VEGF isoform-expressing mice on a Swiss background. 
Fibroblast cultures were genotyped, as described (18), to identify wild-type samples and those 
homozygous for the Vegfa
120
, Vegfa
164
, or Vegfa
188 
allele. Fibroblasts were immortalized and 
oncogenically transformed by retroviral trans- duction with SV40 and HRAS (h-ras; refs. 19, 20). 
The resulting fibrosarcoma cell lines were maintained in high glucose DMEM (Invitrogen) 
medium containing L-glutamine, FCS, and the antibiotics G-418 and puromycin. 
Apoptosis. Apoptotic cell death in response to CA-4-P was evaluated using the cell death 
detection ELISA
plus 
kit (Roche Diagnostics), as pre- viously described (21). Cells were plated at 
10
4 
cells/well in 24-well plates, allowed to adhere for 24 h and then exposed to CA-4-P overnight 
before analysis. 
Subcutaneous tumor transplantation. Fibrosarcoma cells expressing only VEGF120, VEGF164, 
or VEGF188 tumor cells or all three isoforms (control tumor cells) were injected s.c. (1 10
6 
cells 
in 0.05 mL) into the rear dorsum of female severe combined immunodeficiency (SCID) mice (8–
12 weeks old, 20–25 g). 
VEGF-A mRNA and protein analysis. Excised tumors (6–8 mm diameter) were collected into 
RNAlater (Ambion). RNA and protein were isolated from tumor samples using the Mirvana 
PARIS kit (Ambion) and from cell lines in culture using the Cells-to-cDNA11 kit, according to 
the manufacturer’s instructions. VEGF isoforms were amplified using the following PCR primers 
( forward, 5¶CAGGCTGCTGTAACGATGAA3¶; and reverse, 
5¶CTTTCCGGTGAGAGGTCTGG3¶). Approximately 20% of each PCR reaction, together with 
appropriate controls, was then run on 2% agarose gels containing 1 Ag/mL of ethidium bromide 
and products visualized under UV illumination. 
For quantification of VEGF protein in culture supernatants, 2 10
6 
cells were plated in T-175 
flasks, and at 24 h, the medium was replaced with 20 mL of fresh medium. Cells were incubated 
for a further 48 h and then treated with 0.3 mmol/L of suramin for 3 h to release surface matrix-
bound VEGF where medium was collected. VEGF was quantified in the cell me- dium and tumor 
extracts using the Quantikine Immunoassay mouse VEGF ELISA kit (R&D systems), according 
to the manufacturer’s instructions. 
An antibody recognizing all VEGF-A isoforms (p20, Santa Cruz Biotech- nology) was used for 
Western blotting analysis. Cells were plated as above, but at 24 h, the medium was replaced with 
medium without serum. Conditioned media was collected 48 h later and concentrated 50-fold 
(Amicon). Equal amounts of proteins were separated on NuPAGE Novex gels (Invitrogen) and 
transferred to nitrocellulose membranes. Immunore- active bands were detected by enhanced 
chemiluminescence. 
Subcutaneous tumor growth. Subcutaneous tumors were measured using calipers and tumor 
volume (V) was calculated from V = 0.52 d1 d 2 d 3, where d 1, d 2, and d 3 are the three 
orthogonal tumor diameters. Untreated tumor growth curves were fitted to ‘‘Gompertz’’ curves 
[V = exp (a _ [b (exp [_c (t _ d)])])], where a, b, c, and d are fitted variables, and t is time after 
transplant. 
Tumors were treated when they reached 5 to 6 mm in diameter. CA-4-P (50 mg/kg i.p., 10 mL/kg 
in saline) or saline alone, was given once a day for 10 days, with a 2-day gap between the fifth 
and sixth doses. 
Tumor histology and immunohistochemistry. Subcutaneous tumors (6–8 mm diameter) were 
formalin- or zinc-fixed, paraffin-embedded, and stained to identify endothelial cells (rat anti-
mouse CD31 monoclonal antibody; BD PharMingen, Int.) and pericytes [mouse anti-mouse a-
smooth muscle actin (a-sma) monoclonal antibody, Sigma-Aldrich; or rabbit anti- mouse desmin 
polyclonal antibody, Abcam; or rabbit anti-mouse angio- poietin-1 (ANG1) polyclonal antibody, 
Chemicon]. Antibody binding was visualized using 3,3¶-diaminobenzidine (DakoCytomation) 
and signal amplification was achieved via the avidin-biotin complex/horseradish peroxidase 
system (CD31, a-sma, ANG1) or the EnVision system (desmin). Sections were counterstained 
with hematoxylin. 
Mounted sections stained for CD31 and a-sma were quantified according to a random points 
scoring system (22). One hundred and twenty high- power regions of interest were counted per 
tumor to give vascular volume 
as a percentage of tumor volume for CD31 staining. The percentage of necrosis was measured 
from H&E sections by the same method or by delineation of necrotic regions in MATLAB (The 
Mathworks, Inc.). Desmin and ANG1 staining were assessed qualitatively. 
Double staining immunofluorescence employed the CD31 monoclonal antibody described above 
and a FITC-conjugated monoclonal anti-mouse a-sma antibody (Sigma-Aldrich). Sections were 
incubated with a goat anti-rat Alexa-555 Red (Invitrogen) antibody. Sections were mounted in 
4¶,6-diamidino-2-phenylindole Vectashield (Vector Laboratories). 
Window chamber surgery and tumor implantation. SCID mice (12–16 weeks old, 28–32 g) were 
anesthetized using fentanyl-fluanisone and midazolam i.p., as described previously (23). Briefly, 
an aluminum window chamber (total weight, f2 g), holding two parallel glass windows, was 
implanted into a dorsal skin flap. A tumor fragment (f0.5 mm in diameter) from a donor animal 
was implanted onto the exposed panniculus muscle before closing the chamber, allowing a depth 
of f200 Am for tumor growth. Animals were given a s.c. injection of dextrose saline (1 mL) and 
an i.p. injection of buprenorphine (0.1 mL, Vetergesic) to aid recovery and then kept in a warm 
room (28–30jC), until the day of the experiment. 
Intravital microscopy. Donor RBC, acquired via cardiac puncture from donor mice were labeled 
with the fluorescent membrane dye, DiI (Invitrogen), for the measurement of RBC velocity in the 
tumor vasculature, as described previously (24–26). Tumors, at 3 to 5 mm in diameter, were used 
for treatment f6 to 10 days after surgery. 
Treated animals received either CA-4-P (30 mg/kg i.v. at a concentration of 3 mg/mL in 0.9% 
NaCl) or the same volume of 0.9% NaCl. Transmitted light images and video sequences (25 
frames/s) were captured at various magnifications and time points up to 24 h after treatment. For 
the assessment of tumor vascularization in untreated tumors, imaging was performed once per 
day for several days after tumor transplantation. 
Average vessel length, total vascular length, and fractal dimensions were acquired from 
transmitted light images using in-house–developed software, as described previously (23, 27). A 
single vessel was defined as a vascular length with no visible branches. RBC velocities were 
calculated from 20 objective video sequences, using epifluorescence illumination, as described 
previously (26). 
Macromolecular vascular leakage. FITC-labeled dextran (FITC-dex- tran; 40 kDa, 0.013 mol 
FITC/mol dextran; Sigma-Aldrich) was used as a macromolecular marker for determining tumor 
blood vessel barrier function. Following extensive washing to remove low-molecular weight 
contaminants, FITC-dextran (20 mg/mL) was made up in PBS and admi- nistered i.v. to awake, 
restrained mice at 0.05 mL per mouse. Multiphoton fluorescence microscopy, based on a 
modified Bio-Rad MRC 1024MP work- station, was used for imaging, as described previously 
(23). Images were captured every 4 min, at a working excitation wavelength of 890 nm. Emission 
wavelength was 530 to 540 nm. The three-dimensional data consisted of 512 512 11 voxels each 
at a volume of 2.6 2.6 4.5 Am
3
. 
Acquired images were processed, as described previously (28). Changes in image fluorescence 
intensity over time were used as an index of tumor vascular leakage of FITC-dextran. In addition, 
images from the first time point were analyzed for ‘‘contiguity’’ to provide a quantitative 
measure of vascular features in the different tumor lines. First, three-dimensional images were 
segmented into intravascular and extravascular classes, based on image intensities, as described 
previously (28). Then, each voxel within the intravascular class was interrogated to determine the 
fraction of neighboring voxels that were designated as being in the same class (29). The average 
of this fraction, derived from analysis of all the intravascular voxels from a particular tumor 
image, was defined as the contiguity of that tumor’s vasculature. A highly contiguous vasculature 
suggests blood vessels that are well connected, with large diameters and extending into a large 
fraction of the tumor volume (diffuse). 
Statistics. Statistical analysis was carried out using JMP Statistics version 5.1 for the Apple 
Macintosh (SAS Institute, Inc.). The Student’s t test for unpaired data was used to test for 
significant differences between two groups. ANOVA followed by the Tukey-Kramer honest 
significance difference (HSD) test was used to test for significant differences between more than 
two groups. Time courses of intravital microscopy and tumor growth data were fitted to a 
multivariate model (MANOVA) with repeated measures, and differences in responses of the 
different lines were tested for significance using an approximate F test. In all cases, differences 
between groups were described as significant if the probability corresponding to the appropriate 
statistic was <0.05. 
Results 
VEGF isoform expression. Fibrosarcoma cell lines expressing only single isoforms of 
VEGF were generated from primary mouse embryo fibroblasts isolated from isoform-
specific mice. Figure 1B shows that the isoform-specific cell lines expressed the expected 
VEGF isoform transcripts, when grown in vitro or as solid tumors in vivo. Some faint 
bands corresponding to alternative VEGF isoforms were apparent for each of the 
isoform-specific tumor lines when grown in vivo. These most likely derive from 
infiltrating normal mouse cells, as we have observed moderate macrophage infiltration in 
all four tumor types (data not shown). Control tumor 
cell lines predominantly expressed the VEGF164 and VEGF120 mRNA (Fig. 1B). 
Sequencing of the lower band of the doublet that is apparent just below VEGF164 in 
control tumor cell lines revealed a mixed sequence, which corresponded to VEGF164 and 
VEGF120 (data not shown), suggesting that these two isoforms could form a 
heteroduplex under these experimental conditions (30). 
Total VEGF-A protein production, measured by ELISA, in conditioned medium from the 
cells, was not significantly different across the lines, although there was a tendency for 
the highest production in control cells (Fig. 1C). VEGF levels in cell lysates were very 
low by comparison (data not shown). For tumors in vivo, total VEGF levels, measured by 
ELISA, were highest in the VEGF164 line (Fig. 1C), despite equivalent quantitative gene 
expression levels across the lines (see Supplementary Fig. S1). This confirms a previous 
report of high VEGF165 protein levels following transfection of MCF-7 tumor cells with 
VEGF121, VEGF165, or VEGF189 (31). Hypoxia, a common feature of the tumor 
microenvironment, was reported to affect all isoforms of VEGF-A in a similar manner. 
However, repeated oxygen fluctuations have been reported to specifically increase 
VEGF164 in the retina (32) and this may be relevant to our results. 
Western analysis confirmed that the cell lines produced signi- ficant quantities of the 
appropriate VEGF isoform, and no others, when cultured in vitro. However, protein 
expression of the VEGF164 isoform was predominant and VEGF188 expression was low 
and below detection limits in the control cell line (Fig. 1D). 
Attempts to carry out Western analysis on solid tumor extracts were not successful, 
probably because levels were below the sensitivity limits of the assay. 
Vascular morphology. Established subcutaneous tumors were examined for vascularity 
and maturity of their vessel walls using immunohistochemistry. CD31 staining in Fig. 2A 
shows that all tumor types were well-vascularized. However, a-sma staining shows that 
control and VEGF188-expressing tumors were better stabilized with pericytes than 
VEGF120- or VEGF164-expressing tumors. Although this staining was apparent in blood 
vessel walls, there was also substantial staining in a subset of extravascular cells. 
Quantification of staining (Fig. 2B) showed that control and VEGF120 tumors were the 
most vascular (CD31), whereas control and VEGF188 tumors had the most a-sma 
staining. These diffe- rences were statistically significant (see legend for details). Further 
investigations were carried out in the VEGF120-expressing (most diffusible) and the 
VEGF188-expressing (nondiffusible) tumors. Figure 2C shows double-staining for CD31 
and a-sma, which con- firmed the localization of a-sma–positive cells (pericytes) in the 
vasculature of VEGF188 tumors and very little staining in the VEGF120 tumors. The 
spiraling morphology of the a-sma staining in the VEGF188 tumor indicates close contact 
between pericytes and endothelial cells. Figure 2D shows that desmin- and ANG1- 
positive cells were also preferentially found in VEGF188 tumors rather than in VEGF120 
tumors. The staining patterns were also highly suggestive of vascular localization. Taken 
together, these results indicate the association of VEGF120 with sustained expansion of 
the tumor vasculature, whereas VEGF188 is uniquely associated with maturation of the 
blood vessel wall. 
Vascularization of single VEGF isoform–expressing tumors was further analyzed by 
intravital microscopy. Figure 3A and Supple- mentary Fig. S2 illustrate the 
vascularization of VEGF120- and VEGF188-expressing tumors at early and late phases 
of growth in the window chamber. Initial vascularization of the VEGF120- expressing 
tumors was typified by dilated preexisting normal blood vessels, which were prone to 
hemorrhage and indistinct tumor margins (Fig. 3A). In contrast, preexisting normal 
vessels were narrower in the VEGF188 implants, there was very little or no hemorrhage 
and the tumor margins were distinct. As tumors grew, hemorrhage within the VEGF120-
expressing tumors tended to resolve but vascularization was often limited to the periphery 
of the tumor mass. In contrast, VEGF188-expressing tumors were vascularized 
throughout the tumor mass (Fig. 3A). Control and VEGF164-expressing tumors had 
intermediate properties. 
Quantitative morphologic analysis of tumor blood vessels was carried out on two peri-
peripheral regions of interest within each tumor, using a 10 objective, once the tumors 
became optimally vascularized. The vascular patterning in the VEGF188 tumors stood 
out from the others in that the blood vessels were arranged more regularly and individual 
vessels were uniformly narrow. Blood vessels in the other tumor types were irregular in 
width but generally wider and very chaotic in their arrangement. Typical regions of 
interest in a VEGF120- and VEGF188–expressing tumor are shown in Fig. 3B. 
Quantitative analysis revealed no significant difference between the tumor lines in terms 
of mean vascular lengths or fractal dimensions (data not shown). However, the total 
vascular length was higher in the VEGF188 tumors than in any of the other tumor types 
(Fig. 3C ). 
Vascular function. Leakage of i.v. injected 40 kDa fluorescent dextran was monitored in 
VEGF120 and VEGF188 tumors growing in window chambers, using multiphoton 
fluorescence microscopy (Fig. 4). Figure 4A shows typical images with diffuse 
vascularization and rapid leakage in a VEGF120 tumor compared with a VEGF188 
tumor. Contiguity data for the whole group (Fig. 4B), is consistent with the diffuse nature 
of the vasculature in VEGF120 tumors, wider diameter vessels, and leakiness. Figure 4C 
shows the kinetics leakage of FITC-dextran from the intravascular to extravascular space 
in the VEGF120 tumors, which maintained average image intensity in the face of 
vascular clearance of the marker. 
Response to CA-4-P. Vascular response to CA-4-P was deter- mined in tumors growing 
in window chambers. Figure 5A shows typical images from VEGF120- and VEGF188-
expressing tumors at 0, 1, and 24 h following treatment with a moderate single dose of 
CA-4-P (30 mg/kg i.v.). Response in both tumor types was typified by a substantial loss 
of the visible vasculature, primarily at the tumor center, at 1 h after treatment. 
Subsequently, VEGF120- expressing tumors progressed to almost complete avascularity 
and opacity of the central tumor region at 24 h. The vascular mor- phology was 
substantially less affected in the VEGF188 tumors, with very little avascularity by 24 h 
(Fig. 5A). 
Quantitation of the vascular damage in window chamber tumors following CA-4-P 
treatment is shown in Fig. 5B and C for all the tumor types. There is a clear distinction in 
response between the VEGF120 and VEGF164 tumors on the one hand, and the wild-
type and VEGF188 tumors on the other, confirming the observations shown in Fig. 5A 
and Supplementary Fig. S3, which gives additional images from all tumor types. The 
distinction in response of the different tumor types was clearly apparent from both a 
morpho- logic end point (total vessel length; Fig. 5B) and a functional end point (red cell 
velocity; Fig. 5C). 
In order to determine whether these differences in early vascular response to CA-4-P 
translated into differences in therapeutic response, a repeat dosing schedule of CA-4-P 
was administered to mice bearing subcutaneous tumors (Fig. 6A ). VEGF120 and 
VEGF164 tumors were, again, the most sensitive. Interestingly, although the control and 
VEGF188 tumors seemed to be completely resistant to the effects of CA-4-P in the first 
week of treatment, there was some growth retardation during the second week. In a 
separate experiment, VEGF120-expressing tumors were significantly more necrotic than 
VEGF188-expressing tumors at 24 h after a single 100 mg/kg dose of CA-4-P (79.5 F 
9.3% versus 42.8 F 9.3% of tumor volume, respectively, P < 0.05 for Student’s t test). 
However, after five doses of 50 mg/kg CA-4-P, as in Fig. 6A, the necrosis levels in the 
two tumor types were very similar (34.3 F 7.2% and 41.1 F 9.2%, respectively), 
suggesting that the responsiveness of the 188 tumors in the second week was due to 
increased sensitivity of the vasculature. Vascular volume in viable regions of VEGF120-
expressing tumors, as measured by CD31 staining, significantly increased from 7.2 F 
0.5% to 11.0 F 0.6% of tumor volume after a week’s treatment (P < 0.05 for Student’s t 
test). A similar trend in the VEGF188-expressing tumors was only borderline significant. 
Figure 6A also shows that untreated VEGF120- and VEGF164-expressing tumors 
reached a measurable size f4 days before the VEGF188 and control tumors, but then, all 
lines grew at the same rate, consistent with comparable blood flow rates (Supplementary 
Fig. S4). CA-4-P (100 Amol/L) increased apoptosis in all the cell lines growing in vitro, 
with no significant difference in induction rates between the different cell lines (Fig. 6B). 
Discussion 
We have shown that mouse fibrosarcoma cells, which express only single isoforms of 
VEGF, under the control of the endogenous VEGF promoter, produce tumors with very 
different vasculariza- tion patterns, vessel wall structure, and barrier function. The 
method used for production of the tumor lines ensured normal overall VEGF levels. 
Expression of VEGF188, even at very low levels, was uniquely associated with extensive 
recruitment of vascular support cells (pericytes) and tumor resistance to the VDA CA-4-
P. Overall, our results support the view that VEGF188 expression results in a different 
type of vascular bed, which renders the tumor vasculature less susceptible to CA-4-P. 
Our data support previous findings that VEGF120/121 is asso- ciated with hemorrhage 
and vasodilation around tumors (33, 34). They are in agreement with Grunstein et al. (17) 
who found that VEGF120 and VEGF164 were associated with rapid initiation of 
fibrosarcoma growth. In contrast with our findings, Grunstein et al. found poor tumor 
growth associated with a fibrosarcoma cell line expressing only VEGF188. This may be 
due to high levels of VEGF188 in their overexpressing tumor line, leading to overvascu- 
larization of tumors. Indeed, Grunstein et al. found particularly poor vascular filling of 
contrast agent in their VEGF188-expressing tumors. In both studies, endogenous VEGF 
production from normal cells such as macrophages might be expected to contribute to 
vascular development. We found moderate macrophage invasion in all tumor types. 
However, our reverse transcription-PCR results showed that host-derived expression of 
VEGF isoforms was very low in all tumors and this was consistent with substantial 
differences in the vascular characteristics we observed. Quantita- tive differences in 
expression levels may explain why some authors have found that tumor cells transfected 
to overexpress VEGF188/ 189 are nontumorigenic (13), whereas others are tumorigenic 
(34–36). Interestingly, selective down-regulation of VEGF189 expression in a non–small 
cell lung cancer (35) and pancreatic cancer cell line (36) significantly reduced their 
xenotransplant- ability, suggesting that VEGF188/189 does play an important role in 
tumorigenesis. 
We found striking differences in the maturation status of the vascular wall in the different 
VEGF isoform–producing tumors, which related to response to CA-4-P. In particular, the 
presence of VEGF188 resulted in tumor vascular recruitment of mural cells. This is 
consistent with the observations that mice selectively expressing VEGF188 recruit mural 
cells normally to the developing retinal venules and capillaries, whereas mice selectively 
expressing VEGF120 show major defects in mural cell recruitment (15). In addition, we 
showed that ANG1 was expressed in a subset of vessels in VEGF188 tumors and that 
barrier function in the VEGF188 tumors was more effective than in VEGF120 tumors, 
consistent with the observed structural differences. The processes involved in mural cell 
recruitment are complex and poorly understood but undoubtedly involve growth factors 
in addition to VEGF, such as platelet-derived growth factor B (PDGFB; ref. 37). 
Nevertheless, the current result clearly shows a key role for VEGF188 in mural cell 
recruitment in tumors that is associated with a functional effect. In addition, positive 
staining for a-sma was found in a subset of extravascular cells, presumably tumor cells or 
fibroblasts, of the VEGF188-expressing and control tumors but not in the VEGF120- or 
VEGF164-expressing tumors. This suggests a novel role for VEGF188/189 in pericyte 
differentiation. 
Vascular network development was highly influenced by differential expression of VEGF 
isoforms, with VEGF120 being associated with a high vascular volume in established 
subcutane- ous tumors and VEGF188 being associated with regular, narrow vessels and a 
high vascular length per tumor volume. In tumors growing in window chambers, which 
are subjected to high tissue pressure induced by the restraining glass, VEGF120 and 
VEGF164 were associated with a failure to effectively vascularize the center of tumors. 
This is likely to be due to the fragility of blood vessels, 
suggested by their lack of mural cells. Expression of VEGF164 was associated with a 
relatively low vascular volume (similar to VEGF188) but rapid initiation of tumor growth 
(similar to VEGF120). This suggests a highly proliferating phenotype for VEGF120- and 
VEGF164-expressing tumor cells, at the expense of vascular maturation. This is 
consistent with our recent in vitro data, showing higher proliferation rates for VEGF120- 
or VEGF164- expressing tumor cells than VEGF188-expressing or control cells (ref. 20; 
Supplementary Table S1). Any differences between the vasculature in VEGF120- and 
VEGF164-expressing tumors were subtle. However, the difference in vascular volume 
and the quali- tative observation of less hemorrhage in the VEGF164 tumors does suggest 
some differences in their control of vascular maturation, an observation that warrants 
further investigation. 
Several explanations for the different effects of individual VEGF isoforms on tumor 
vascular morphology and function can be envisaged. In the developing brain of 
Vegfa188/188 mice, there is an increased extension of endothelial filopodia and vascular 
branch formation, compared with brains of Vegfa120/120 mice (16), and this might also 
apply to tumor angiogenesis. There is also evidence for differential activation of VEGF 
receptors by the different isoforms. First, VEGF164/165 (and probably VEGF188/189) 
but not VEGF120/121, can bind to the accessory receptor, neuropilin-1 (NRP1; ref. 38). 
However, impaired signaling through the NRP-1 receptor could not account for all 
vascular branching defects in Vegfa120/120 mouse embryos (16) and would not explain the 
signi- ficant differences between VEGF164- and VEGF188-expressing tumors. Heparan 
sulfate proteoglycans on the cell surface have also been implicated in modifying VEGF 
signaling, partly by controlling the distribution and bioavailability of secreted VEGF (39, 
40). Other possibilities, which remain poorly understood, include the translocation of 
intracellular VEGF188/189 to the nucleus (31) and the cross-talk of VEGF signaling 
pathways with integrins (41). 
In interpreting our data, we cannot discount the possibility that an adaptive response to 
the depletion of VEGF120 or VEGF164, resulting in increased expression of alternative 
vascular-related growth factors in the VEGF188-expressing cell line, could explain our 
results. Notwithstanding potential affinity issues of the VEGF antibody used in the 
ELISA kit for VEGF188, VEGF protein expres- sion in the VEGF188 line in vivo seems 
to be relatively low (Fig. 1C), highlighting this possibility. However, real-time PCR data 
(Supple- mentary Fig. S1) did not reveal any alternative candidate genes for explaining 
our results. Transformation significantly lowered VEGFR2, NRP1, TIE2, Ang2, and 
Hey2 gene expression across all the lines, but only Ang2 and PDGFB differed in their 
expression levels between the VEGF188-expressing tumor cells and the other cell types. 
Increased Ang2 and lowered PDGFB levels, as found in the VEGF188-expressing line, 
are unlikely explanations for the observed increase in pericyte recruitment of this line in 
vivo because Ang2 is normally associated with vascular immaturity and PDGFB is a 
well-known chemoattractant for pericytes. In addition, administration of VEGF receptor 
kinase inhibitors in vitro and in vivo and a pan-isoform neutralizing antibody for VEGF 
in vitro, equalized both tumor cell proliferation in vitro and vascular morphology in vivo, 
across the different cell lines, suggesting that baseline differences in these variables were 
VEGF-induced (Supplementary Fig. S5; Supplementary Table S1). 
Differential expression of VEGF isoforms was clearly associated with outcome following 
treatment with the VDA, CA-4-P, both in terms of initial vascular response and tumor 
growth response to a repeated dosing schedule. A modest growth response, as observed 
here even for the VEGF120-expressing tumors, is not unusual for VDAs and could mask 
significant cell-killing effects. This is thought to be due primarily to poor clearance of 
dead cells because of blood flow reduction (42). The presence of VEGF188, even at low 
levels in the control tumors, conferred resistance to treatment. Although speculative, it is 
possible that very tight association of VEGF188 with the cell surface minimizes the 
amount of protein necessary for a given outcome, as well as negatively feeding back on 
VEGF188 production. Necrosis data showed that VEGF188 tumors suffered vascular 
damage in the first week of treatment despite the lack of growth response. This may have 
been sufficient to sensitize the tumors to continued treatment. CD31 staining indicated an 
increase in vascularization of re-growing viable tumor regions after the first week of 
treatment, which could relate to homing of bone marrow–derived vascular progenitor 
cells following CA-4-P treat- ment, as previously reported (43). This increased 
vascularization may also relate to increased sensitivity to CA-4-P in the second week of 
treatment, although potential mechanisms require further investigation. Finally, the larger 
size of tumors at the start of treatment in the second week may have contributed to 
increased sensitivity (44). 
Previously, we hypothesized that high vascular permeability and the immaturity of the 
vascular wall were major factors associated with the sensitivity of tumor vasculature to 
CA-4-P and similar agents (45, 46). The current results substantiate this hypothesis, 
and furthermore, suggest that VEGF188 expression is uniquely predictive of treatment 
outcome. Interestingly, several studies have suggested that VEGF189 expression in 
human cancers is associated with tumor progression and poor outcome from conventional 
treatments (47–50). 
In conclusion, the main VEGF isoforms, under the control of the endogenous VEGF 
promoter, have very different effects on vascularization of fibrosarcomas in an animal 
model. In particular, VEGF188 and/or associated gene expression plays a crucial role in 
tumor vascular maturation and conferring resistance to the VDA, CA-4-P. Therefore, 
VEGF isoform expression may be useful for predicting tumor susceptibility to vascular-
disrupting cancer therapy. 
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 Figure 1. VEGF isoform expression. A, exon structure of murine VEGF isoforms. B, VEGF isoform–specific reverse 
transcription-PCR of cDNA extracted from control and single VEGF isoform–expressing tumor cell lines grown 
in vitro and solid tumor extracts from all four tumor types grown subcutaneously in SCID mice. Although bands 
corresponding to VEGF188, VEGF164, and VEGF120 are evident in control cell lines (B), only the relevant isoform is 
seen in each isoform-specific line. Alternative isoforms are just visible in each isoform-specific line when grown in 
vivo (B). Standards of known sizes were run in parallel (number of base pairs shown in the vertical bar). C, total VEGF 
protein level in conditioned medium from the different cell lines in culture and from tumor extracts, measured by 
ELISA. Columns, mean for five repeat cell culture experiments and for tumors (n = 5) in each group for tumor extracts; 
bars, SE. ANOVA showed no significant differences between groups in the cell culture experiments. *, P < 0.05, 
significant differences between groups for extracts of solid tumors (ANOVA followed by Tukey-Kramer HSD test). D, 
cell-conditioned media were concentrated 50-fold and analyzed by Western blotting using a VEGF antibody that 
recognizes all isoforms of VEGF-A. Mouse recombinant VEGF120 (r120) and VEGF164 (r164) migrated similarly to 
the medium conditioned by the single isoform–expressing tumor cells.    
 Figure 2. Immunohistochemical analysis of vascular wall maturity in tumors grown subcutaneously in SCID mice. A, 
near-adjacent sections from all four tumor types were stained for CD31 
and a-sma (brown). Arrows, the same blood vessel in each pair of images. VEGF188-expressing and control tumors 
expressed more a-sma than the other tumor types, some but not all of which were associated with CD31-positive blood 
vessels. B, quantitative analysis of CD31 and a-sma staining for the whole group, stained as in A. Columns, mean for 
tumors in each group (n = 8); bars, SE. *, P < 0.05, significant differences between groups (ANOVA followed by 
Tukey-Kramer HSD test). C, double immunofluorescence staining for CD31 (red) and a-sma (green) with nuclei 
stained with 4¶,6-diamidino-2-phenylindole (blue). Inset, the area indicated at higher magnification, illustrating the 
spiraling morphology of pericytes. D, desmin staining and Ang1 staining (brown) for VEGF120- and VEGF188-
expressing tumors. Arrows, examples of vessels staining positively for desmin and Ang1.   
 Figure 3. Vascular morphology of tumors growing in the dorsal skin flap window chambers in SCID mice. A, low-
power ( 2.5 objective) transmitted light images of tumors at 6 and 9 d after tumor transplantation. *, hemorrhage in the 
VEGF120-expressing tumor. Images show a well-vascularized center in the VEGF188-expressing tumor at day 9, as 
compared with the VEGF120-expressing tumor at the same time (see also Supplementary Fig. S2). B, high-power ( 10 
objective) images of VEGF120- and VEGF188-expressing tumors showing narrower vessels and a more regular 
arrangement of the vascular network in the VEGF188-expressing tumor. C, quantitative analysis of total vascular 
length in regions of interest such as those in B, for the whole group of tumors. Columns, mean for tumors in each group 
(n = 6–9); bars, SE. *, P < 0.05, significant differences between the groups. Total vascular length was significantly 
higher in VEGF188-expressing tumors than in the other tumor types (ANOVA followed by Tukey-Kramer HSD test). 
  
 Figure 4. In vivo multiphoton fluorescence imaging of VEGF120- and VEGF188-expressing tumors growing in window 
chambers in SCID mice. A, maximum projection images from two tumors at different times (midpoint of the time frame 
for image acquisition) following i.v. injection of 40 kDa of FITC-dextran. Extensive leakage of FITC-dextran from the 
tumor vasculature into the interstitium could be seen with time in the VEGF120-expressing tumor but not in the 
VEGF188-expressing tumor. B, image contiguity (columns, mean; bars, SE) at the first time point after injection of 
FITC-dextran (2.5 min) for the whole tumor group (n = 5–7 tumors in each group). Contiguity was significantly higher 
in VEGF120 tumors than in VEGF188 tumors (*, P = 0.0005; Student’s t test for unpaired data). C, the kinetics of 
FITC-dextran leakage for the whole tumor group. Intensities were averaged gray levels in whole three-dimensional 
images of each tumor, normalized to the first time point (mean for n = 5–7 tumors in each group; bars, 1 SE). The 
curves for the two groups were significantly different (P < 0.05, MANOVA with repeated measures). 
 
 
   
 Figure 5. Response of the different tumor types growing in window chambers in SCID mice to a single dose of 30 
mg/kg i.v. CA-4-P. A, typical low-power ( 2.5 objective) images of VEGF120- and VEGF188-expressing tumors after 
CA-4-P treatment. There was a reduction in the visible vasculature at 1 h after treatment in both tumor types and 
extensive avascular regions in VEGF120- but not VEGF188-expressing tumors by 24 h (*). Supplementary Fig. S3 
shows that the response of VEGF164 tumors was similar to VEGF120 tumors and the response of control tumors was 
similar to VEGF188 tumors. B and C, quantitative analysis of vascular length and red cell velocity for all tumor types. 
Points, mean for tumors in each group (n = 4–6); bars, SE. *, P < 0.05, curves for VEGF120- and VEGF164-expressing 
tumors were significantly different from those for VEGF188-expressing and control tumors over these regions 
(MANOVA with repeated measures). 
 
 
   
  
Figure 6. A, tumor volume growth curves for all tumor types growing subcutaneously in SCID mice F CA-4-P 
treatment [10 fractions of 50 mg/kg of CA-4-P i.p. or equal volumes of saline, at times indicated (arrows)]. Untreated 
tumor growth curves (solid lines) were fitted to Gompertz curves, as described in the text. The lag phase in tumor 
growth was shorter for VEGF120 and VEGF164 tumors than for control and VEGF188 tumors. However, at 18 d, 
untreated tumor growth rate was 73.4 F 7.8, 86.2 F 8.0, 86.3 F 18.3, 59.2 F 5.4 mm
3
/d for control, VEGF120-, 
VEGF164-, and VEGF188-expressing tumors, respectively. These differences were not significant (P > 0.05, 
ANOVA), which was consistent with similar blood flow rates in the four cell lines (see Supplementary Fig. S4). 
VEGF120- and VEGF164-expressing tumors responded better to CA-4-P treatment (broken lines) than VEGF188-
expressing and control tumors. Points, mean for tumors in each group, representing combined data from two separate 
experiments (n = 9–11); bars, SE. *, P < 0.05, significant differences were obtained between untreated and treated 
curves over the regions indicated (MANOVA with repeated measures). B, apoptosis induced by CA-4-P (100 Amol/L) 
in single isoform–expressing tumor cells and control cells in vitro. Results are plotted as rates relative to those in 
untreated cells. Columns, mean for seven repeat experiments; bars, SE. There were no significant differences across the 
groups (P > 0.05, ANOVA). 
 
 
